|
| Study design | Resveratrol dose/preparation | Duration | Subjects | Purpose | Main results | References |
|
| Young and aged healthy individuals |
| R, DB, PC, CO | Trans-resveratrol from Biotivia Bioceuticals 250 mg or 500 mg | 21 days | (24)
18-25 years healthy | Ability to increase cerebral blood flow and modulate mental function | Increase in cerebral flow, no effect in cognitive function | Kennedy et al., 2010 [94] |
|
| R, DB, PC, CO | Trans-resveratrol 250 mg/day or trans-resveratrol 250 mg/day with 20 mg piperine | 21 days | (23)
Healthy subjects aged 19-34 years | Effect of piperine on the efficacy and bioavailability of resveratrol | Piperine enhances the effect of resveratrol on cerebral blood flow but no effect on bioavailability and cognition | Wightman et al., 2014 [95] |
|
| Study in older adults | 200 mg of resveratrol per day | 26 weeks | (46)
Healthy overweight subjects aged 50-75 years | Test whether resveratrol would improve memory performance in older adults | Resveratrol ameliorates memory performance in combination with improved glucose metabolism and increased hippocampal functional connectivity in healthy overweight old people | Witte et al., 2014 [107] |
|
| Patients with cognitive decline and postmenopausal women |
| R, DB, PC | 72 g of active grape formulation | 6 months | (10) Adults with mild cognitive decline with mean age of 72.2 years | Evaluate the effects of grapes on regional cerebral metabolism | Grapes could possess a protective effect against early pathologic metabolic decline | Lee et al., 2017 [108] |
|
| R, PC, intervention trial | 75 mg twice daily of trans-resveratrol | 14 weeks | (80) Postmenopausal women between 45 and 85 years old | Test the effects of resveratrol on cognition, mood, and cerebrovascular function in postmenopausal women | Resveratrol was well tolerated and able to improve cognition which was related to the improvement of cerebrovascular function. Mood was improved but not significantly. | Evans et al., 2017 [109] |
|
| Patients with MCI |
| R, DB, interventional study | 200 mg of resveratrol per day | 26 weeks | (40)
Old patients with MCI | Assess if resveratrol improves long-term glucose control, resting-state functional connectivity of the hippocampus, and memory function in patients with MCI | Resveratrol supplementation decreased glycated hemoglobin A1c, preserved hippocampus volume, and improved hippocampus RSFC in patients with MCI | Koebe et al., 2017 [112] |
|
R, DB
Phase 1 | Bioactive dietary polyphenol preparation (BDPP) at low, moderate, and high doses | 4 months | (48)
55-85 years MCI | Safety and efficacy in treating mild cognitive impairment | — | NCT02502253 [110] |
|
R, DB, PC
Phase 4 | Resveratrol or omega-3 supplementation or caloric restriction | 6 months | (330)
50-80 years MCI | Effects on brain function | — | NCT01219244 [111] |
|
| Patients with mild to moderate AD |
R, DB, PC, MC
Phase 2 | Resveratrol 500 mg/day with escalation by 500 mg increments ending with 2 g/day | 52 weeks | (119)
Over 49 years mild to moderate AD | Assess efficacy and safety | No effect on cognitive score, decrease of CSF and plasma Aβ40 levels | Turner et al., 2015 [113] |
|
| R, DB, PC Phase 2 | Resveratrol 500 mg daily (orally) with a dose elevation by 500 mg every 13 weeks until a final dose of 1000 mg twice daily was reached for the final 13 weeks. | 52 weeks | (119)
Adults older than 49 years old with a diagnosis of mild to moderate dementia due to AD | Evaluation of safety and tolerability of resveratrol and its effects on AD biomarkers and also on clinical outcomes | Resveratrol was well tolerated and safe, it was detected in the cerebrospinal fluid (nM), it changed the AD biomarker paths, it modified the CNS immune response, and it maintained the BBB integrity; however, more research is needed | Sawda et al., 2017 [114] |
|
R, DB, PC
Phase 3 | Longevinex brand resveratrol supplement (resveratrol 250 mg/day) | 52 weeks | (50)
50-90 years mild to moderate AD on standard therapy | Effects on cognitive and global functioning | — | NCT00743743 [115] |
|
R, DB, PC
Phase 3 | Resveratrol with malate and glucose | 12 months | (27)
50-90 years mild to moderate AD | Ability to slow the progression of AD | — | NCT00678431 [116] |
|
